- Why Research
- Our Impact
- Get Involved
- About BCRF
- Contact Us
- Cancer Divides. We Unite.
You are here
Christina Curtis, PhD, MSc
Assistant Professor, Medicine and Genetics
Stanford University, School of Medicine
Seeking to understand the causes of drug resistance in breast cancers.
Studies are ongoing to validate a potential biomarker of resistance.
These studies will help define new therapeutic targets and better treatments.
Tumors are composed of a mixture of cells that are genetically unique and have different properties. This intra-tumor complexity poses numerous clinical challenges, including drug resistance. Although drug resistance represents a major cause of breast cancer mortality, the underlying mechanisms remain poorly understood.
Dr. Curtis and her team are working to characterize the intrinsic molecular features that cause some breast tumor cells to be resistant to chemotherapeutic agents and/or targeted therapies. She is hoping to better understand how populations of cancer cells evolve under the selective pressure imposed by therapy, leading to the outgrowth of resistant cells, followed by clinical resistance and disease recurrence.
Towards these goals, Dr. Curtis is combining advanced genomic techniques, functional assays, and computational methods to analyze existing breast cancer datasets as well as longitudinal breast tumor samples taken before, during, and after the course of therapy.
Using this framework, they have demonstrated that tumors progress or ‘evolve’ according to two main paths and they have identified candidate biomarkers and a potentially widespread mechanism of resistance to a commonly used type of chemotherapy. She is now in the process of validating these findings in independent patient cohorts and will further extend these approaches to develop and test predictive signatures. These effort will enable more precise treatment decisions, thereby sparing patients ineffective therapy, and inform the development of patient-tailored treatment strategies.
Dr. Curtis is an Assistant Professor of Medicine and Genetics in the School of Medicine at Stanford University where she leads the Cancer Systems Biology Group and serves as Co-Director of the Molecular Tumor Board at the Stanford Cancer Institute. She received her doctorate in Molecular and Computational Biology in 2007 and completed a postdoctoral fellowship in Computational Biology at the University of Cambridge in 2010. Dr. Curtis was the recipient of several young investigator awards, including the 2012 V Foundation for Cancer, V Scholar Award and the 2012 STOP Cancer Research Career Development Award.
Dr. Curtis’s laboratory pursues innovative experimental approaches and data-driven modeling to address outstanding questions in cancer systems biology. In particular, her research seeks to delineate mechanisms of tumor progression and therapeutic resistance. For example, she and her team have developed an experimental and computational framework to interrogate tumor evolutionary dynamics and the timeline of neoplastic progression. They are also developing approaches to model therapeutic resistance. By coupling this approach with high-resolution genomic profiling of patient samples, this research will enable a paradigm shift in patient stratification and will ultimately inform optimal treatment strategies.
Another aspect of her research has focused on the integration of diverse genomic data types to elucidate inter-individual variation and mechanisms of tumorigenesis. For example, she leads a seminal study that redefined the molecular map of breast cancer through a detailed characterization of the genomic and transcriptomic landscape of 2,000 breast cancers. Using integrative genomics and statistical approaches, this work identified novel subtypes of breast cancer with distinct clinical outcomes and subtype-specific driver genes. Ongoing efforts in this area will guide the development of novel targeted therapeutics and improved prognostic signatures.
BCRF Investigator Since
The ULTA Beauty Award